TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lupin Limited ( (IN:LUPIN) ) has shared an announcement.
Lupin Limited has launched Risperidone for extended-release injectable suspension in the U.S., marking the first product from its proprietary PrecisionSphere™ platform. This launch, supported by a 180-day CGT exclusivity, underscores Lupin’s commitment to expanding its portfolio of complex injectables and enhancing global access to advanced long-acting treatments. The product is bioequivalent to Risperdal Consta® and is used for treating schizophrenia and bipolar I disorder, with significant market potential in the U.S.
More about Lupin Limited
Lupin Limited is a global pharmaceutical company known for its focus on developing complex generics and specialty products. The company operates in the healthcare industry, with a strong emphasis on creating innovative drug delivery systems, such as its proprietary long-acting injectable platform, PrecisionSphere™.
Average Trading Volume: 20,891
Technical Sentiment Signal: Buy
Current Market Cap: 929.9B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.